Synlett 2017; 28(17): 2330-2334
DOI: 10.1055/s-0036-1588484
letter
© Georg Thieme Verlag Stuttgart · New York

Scalable Synthesis of 6,6-Dimethylbicyclo[3.1.0]hexan-3-one

Steven M. Mennen*
a   Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, USA   eMail: smennen@amgen.com
,
Athimoolam Arunachalampillai
b   Chemical Development, Syngene Intl. Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
,
Deborah M. Choquette
a   Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, USA   eMail: smennen@amgen.com
,
Harikrishna Muppalla
b   Chemical Development, Syngene Intl. Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
,
Krishna Sheena
b   Chemical Development, Syngene Intl. Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 26. April 2017

Accepted after revision: 02. Juni 2017

Publikationsdatum:
18. Juli 2017 (online)


Abstract

A simple five-step process for the conversion of technical grade (+)-3-carene into 6,6-dimethylbicyclo[3.1.0]hexan-3-one was developed. A robust process was required that delivered the 6,6-dimethylbicyclo[3.1.0]hexan-3-one, minimized chromatography, reduced the excess of silver salts, and avoided toxic chromium oxidants. A simple and scalable process that relies on crystallization and distillation was developed and demonstrated to produce hundreds of grams of 6,6-dimethylbicyclo[3.1.0]hexan-3-one.

Supporting Information

 
  • References and Notes

  • 1 Bolli M. Lehmann D. Mathys B. Mueller C. Nayler O. Velker J. Weller T. WO 2006100635A2, 2006
  • 2 Edwards MG. Paxton RJ. Pugh DS. Whitwood AC. Taylor RJ. K. Synthesis 2008; 3279
  • 3 Charette A. Wilb N. Synlett 2002; 176
    • 4a Fürstner A. Hannen P. Chem. Eur. J. 2006; 12: 3006
    • 4b Blaszykowski C. Harrak H. Brancour C. Nakama K. Dhimane A.-L. Fensterbank L. Malacria M. Synthesis 2007; 2037
  • 5 Rigby JH. Bellemin A. Synthesis 1988; 188
  • 6 Bolli M. Lehmann D. Mathys B. Mueller C. Nayler O. Velker J. Weller T. WO 2006100635A2, 2006
    • 7a Kuczyński H. Walkowicz M. Walkowicz C. Nowak K. Siemion IZ. Rocz. Chem. 1964; 38: 1625
    • 7b Walkowicz M. Kuczyński H. Walkowicz C. Rocz. Chem. 1967; 41: 927

    • Bromohydrin synthesis:
    • 7c Crocker W. Grayson DH. Tetrahedron Lett. 1969; 51: 4451

    • Synthesis of ketone from alcohol (post pinacol):
    • 7d Lochyński S. Jarosz B. Walkowicz M. Piatkowski K. J. Prakt. Chemie. 1988; 284
  • 8 Current costs from sigmaaldrich.com (Item: 94415-1ML at $54.10; Item: W382108-1KG at $97).
  • 9 See Supporting Information for GC method details.
  • 10 Unidentified impurity was present at a relative retention time (RRT) of 0.87 min by gas chromatography.
  • 11 (1S,3R,4R,6R)-4-Bromo-3,7,7-trimethylbicyclo[4.1.0]heptan-3-ol (2) To a clean and dry 45 L glass reactor was charged 1,4-dioxane (8,000 mL, 8.0 V), water (4,000 mL, 4.0 V), (+)-3-carene (1,000 g, 7.3 mol), and CaCO3 (977 g, 9.8 mol), and the suspension was cooled to 10 °C. NBS (1,698 g, 9.5 mol) was added in portions over 1 h while maintaining the internal temperature. At the end of addition, the resulting mixture was warmed to 20 °C and maintained for 3 h, and the progress of the reaction was monitored by GC until (+)-3-carene was not detected. The reaction mixture was then diluted with water (20,000 mL, 20 V) and extracted twice with PE (12,000 mL, 12 V). The combined organic extracts were washed twice with 5% w/w Na2S2O3 solution (10,000 L, 10 V), dried over anhydrous Na2CO4, and concentrated under vacuum at 35 °C to get the crude product. The crude product was dissolved in hexane (4,000 mL, 4 V), cooled to –40 °C, and stirred for 30 min. The solid was filtered, washed with chilled hexane (1,000 mL, 1 V), and dried at 25 °C for 5 h to get 850 g of (1S,3R,4R,6R)-4-bromo-3,7,7-trimethylbicyclo[4.1.0]heptan-3-ol as off-white solid as main crop with 95% GC purity. The mother liquor was cooled to –40 °C, stirred for 30 min, filtered, dried, and isolated another 100 g as off-white solid (second crop) with 94% purity by GC. Both the crops material were mixed and taken forward into the next step. TLC: PE/EtOAc (8:2); Stain solution: PMA (10% EtOH), yield 950 g (56%). 1HNMR of first crop (300 MHz, CDCl3): δ = 0.69 (t, J = 7.26 Hz, 1 H), 0.80–0.88 (m, 1 H), 0.99 and 1.02 (s, 6 H), 1.30 (s, 3 H), 1.41 (d, J = 4.92 Hz, 1 H), 2.20 (dd, J = 14.63 and 9.72 Hz, 1 H), 2.34–2.49 (m, 2 H), 4.06 (dd, J = 10.79 and 7.95 Hz, 1 H).
  • 12 Current costs from sigmaaldrich.com of 99% purity silver salt: AgNO3(S6506-500G at $1,071.20/0.5kg) costs $546/mol 3 using 1.5 equiv AgNO3 and Ag2O (item: 221163-1KG at $2,195.00/kg) costs $1,017/mol 3 using 2.0 equiv Ag2O.
    • 13a Harding KE. Trotter JW. J. Org. Chem. 1977; 42: 4157
    • 13b Harding KE. Strickland JB. Pommerville J. J. Org. Chem. 1988; 53: 4877

      For examples of AgNO3-mediated ring expansion, see:
    • 14a Pauvert M. Dupont V. Guingant A. Synlett 2002; 1350
    • 14b Morimoto T. Yamazaki A. Achiwa K. Chem. Pharm. Bull. 2004; 52: 1367
  • 15 Throughout the investigation, an unidentified impurity was present at 0.95 RRT. The impurity had the same nominal mass by low resolution GC–MS as the desired product 3. The impurity was present in varying amounts and is hypothesized to be the result of either elimination of HBr or epoxidation.
  • 16 Distillation conditions: Batch temperature 54–56 °C, pressure 5–2 mbar, isolated yield 85% on 10 g scale. Equipment: Short path distillation head with a combined cold-coil and Liebig condenser and affixed with a three-port distribution adapter.
  • 17 Distillation conditions: batch temperature 85–105 °C, pressure 10–1 mbar, isolated yield 88% on 7 g scale. Equipment: Short path distillation head with a combined cold-coil and Liebig condenser and affixed with a three-port distribution adapter.
  • 18 International Conference on Harmonization (2014). M7(R4): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.
    • 19a Dess DB. Martin JC. J. Org. Chem. 1983; 48: 4155
    • 19b Dess DB. Martin JC. J. Am. Chem. Soc. 1991; 113: 7277
    • 19c Boeckman RK. Shao S. Mullins J. J. Org. Synth. 2000; 77: 141
    • 20a Plumb JB. Harper DJ. Chem. Eng. News. 16.07.1990; 3
    • 20b Uyanik M. Ishihara K. Aldrichimica Acta 2010; 43: 83
    • 20c Boeckman RK. Shao S. Mullins J. 2000; 77: 141
  • 21 Bercot EA. Bio M. Chan J. Colyer J. Fang Y. Mennen S. Milburn RR. Tedrow J. Riahi B. WO 2013173672, 2013